The unsolved cyclosporine-induced kidney injury: is paricalcitol a feasible new renoprotective option?
The management of cyclosporine A (CsA)-induced nephrotoxicity remains one of the main challenges in kidney transplantation. The animal study by Park et al. proposes that paricalcitol, a vitamin D analog with renoprotective actions reported in other conditions, attenuates CsA-induced kidney injury via the suppression of inflammatory, fibrotic, and apoptotic factors. Before paricalcitol can be considered a feasible new therapeutic option for post-transplantation nephropathy, these interesting data require further studies assessing other mechanisms of CsA-induced nephrotoxicity.
Institute of Pharmacology and Experimental Therapeutics, Institute of Biomedical Research on Light and Image (IBILI), Medicine Faculty, Coimbra University, 3000-354 Coimbra, Portugal. freis@fmed.uc.pt
Flávio N F
FN
Reis
D050071:Bone Density Conservation Agents; D016572:Cyclosporine / Q000633:toxicity*; D004872:Ergocalciferols / Q000627:therapeutic use*; D005355:Fibrosis; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced / Q000188:drug therapy*; D016030:Kidney Transplantation / Q000009:adverse effects; D020011:Protective Agents
D050071:Bone Density Conservation Agents; D004872:Ergocalciferols; D020011:Protective Agents; C084656:paricalcitol; D016572:Cyclosporine